Physician profile
William S Bevers
NPI 1922070317
$8,660.39
in general payments reported to CMS, 2019-2025
48 companies · $961 in 2025
The $961 reported for 2025 was more than what 85% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $548 · 2020: $851 · 2021: $1,817 · 2022: $1,833 · 2023: $1,520 · 2024: $1,133 · 2025: $961.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,613.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,612.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,098.63 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $929.80 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Pfizer INC. | $885.48 | 2019-2025 | |
| Abbvie INC. | $827.23 | 2021-2025 | Vraylar, Qulipta, Ubrelvy |
| Lilly USA, LLC | $532.56 | 2019-2025 | Zepbound, Jardiance, Mounjaro |
| Astellas Pharma US INC | $420.80 | 2019-2024 | Veozah |
| Glaxosmithkline, LLC. | $405.99 | 2019-2024 | Trelegy Ellipta, Shingrix, Arexvy |
| Otsuka America Pharmaceutical, INC. | $342.22 | 2020-2025 | Rexulti, Abilify Asimtufii |
| Takeda Pharmaceuticals U.S.A., INC. | $332.00 | 2019-2025 | Trintellix |
| Bayer Healthcare Pharmaceuticals INC. | $258.67 | 2021-2025 | |
| Merck Sharp & Dohme LLC | $246.81 | 2019-2023 | Belsomra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $236.88 | 2019-2024 | Jardiance |
| Amgen INC. | $177.39 | 2019-2025 | Prolia, Evenity, Otezla |
| Biohaven Pharmaceutical Holding Company LTD. | $173.23 | 2022 | |
| Exact Sciences Corporation | $157.25 | 2023-2025 | Cologuard Collection Kit |
Show all 48 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Bevers listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.